Bristol-Myers Squibb Co (BMY)
44.59
-0.12
(-0.27%)
USD |
NYSE |
May 15, 14:27
Bristol-Myers Squibb Gross Profit (Quarterly): 8.933B for March 31, 2024
Gross Profit (Quarterly) Chart
Historical Gross Profit (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.933B |
December 31, 2023 | 8.732B |
September 30, 2023 | 8.46B |
June 30, 2023 | 8.35B |
March 31, 2023 | 8.771B |
December 31, 2022 | 8.813B |
September 30, 2022 | 8.865B |
June 30, 2022 | 9.167B |
March 31, 2022 | 9.177B |
December 31, 2021 | 9.629B |
September 30, 2021 | 9.333B |
June 30, 2021 | 9.251B |
March 31, 2021 | 8.232B |
December 31, 2020 | 8.158B |
September 30, 2020 | 8.038B |
June 30, 2020 | 7.43B |
March 31, 2020 | 7.119B |
December 31, 2019 | 5.453B |
September 30, 2019 | 4.217B |
June 30, 2019 | 4.301B |
March 31, 2019 | 4.096B |
December 31, 2018 | 4.363B |
September 30, 2018 | 4.043B |
June 30, 2018 | 4.079B |
March 31, 2018 | 3.609B |
Date | Value |
---|---|
December 31, 2017 | 3.848B |
September 30, 2017 | 3.675B |
June 30, 2017 | 3.575B |
March 31, 2017 | 3.664B |
December 31, 2016 | 3.837B |
September 30, 2016 | 3.617B |
June 30, 2016 | 3.665B |
March 31, 2016 | 3.339B |
December 31, 2015 | 3.335B |
September 30, 2015 | 2.972B |
June 30, 2015 | 3.15B |
March 31, 2015 | 3.194B |
December 31, 2014 | 3.292B |
September 30, 2014 | 2.914B |
June 30, 2014 | 2.898B |
March 31, 2014 | 2.843B |
December 31, 2013 | 3.168B |
September 30, 2013 | 2.89B |
June 30, 2013 | 2.94B |
March 31, 2013 | 2.768B |
December 31, 2012 | 3.116B |
September 30, 2012 | 2.749B |
June 30, 2012 | 3.198B |
March 31, 2012 | 3.948B |
December 31, 2011 | 4.087B |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Quarterly) Range, Past 5 Years
4.217B
Minimum
Sep 2019
9.629B
Maximum
Dec 2021
8.021B
Average
8.596B
Median
Gross Profit (Quarterly) Benchmarks
Amgen Inc | 4.247B |
Gilead Sciences Inc | 5.134B |
Johnson & Johnson | 14.87B |
Eli Lilly and Co | 7.094B |
2seventy bio Inc | 7.936M |